Gilder Gagnon Howe & Co. LLC cut its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 564,038 shares of the medical equipment provider’s stock after selling 4,086 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned about 1.69% of AxoGen worth $10,914,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of AXGN. Thompson Davis & CO. Inc. raised its stake in shares of AxoGen by 575.0% in the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 5,750 shares in the last quarter. Bank of America Corp DE raised its stake in shares of AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares in the last quarter. Neuberger Berman Group LLC acquired a new position in shares of AxoGen in the second quarter valued at $201,000. Finally, Nationwide Fund Advisors raised its stake in shares of AxoGen by 5.5% in the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after purchasing an additional 774 shares in the last quarter. Institutional investors own 67.44% of the company’s stock.

AxoGen, Inc. (AXGN) remained flat at $$24.80 during trading on Wednesday. The company’s stock had a trading volume of 148,900 shares, compared to its average volume of 200,010. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. AxoGen, Inc. has a 52 week low of $8.05 and a 52 week high of $25.15.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The firm had revenue of $16.05 million during the quarter, compared to analyst estimates of $15.55 million. AxoGen’s quarterly revenue was up 43.2% compared to the same quarter last year. equities analysts anticipate that AxoGen, Inc. will post -0.31 EPS for the current fiscal year.

In other AxoGen news, Director Robert James Rudelius sold 16,143 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $18.00, for a total transaction of $290,574.00. Following the completion of the transaction, the director now directly owns 43,273 shares in the company, valued at $778,914. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.33% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “AxoGen, Inc. (AXGN) Shares Sold by Gilder Gagnon Howe & Co. LLC” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/15/axogen-inc-axgn-shares-sold-by-gilder-gagnon-howe-co-llc.html.

A number of research analysts recently commented on AXGN shares. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Roth Capital restated a “buy” rating and issued a $21.00 target price (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Leerink Swann started coverage on AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 target price for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $18.00 target price on shares of AxoGen in a research note on Monday, August 21st. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $18.00.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN).

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.